following a full submission
febuxostat film-coated tablet (Adenuric®) is accepted for restricted use within NHS Scotland.
Indication under review: the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumour Lysis Syndrome (TLS).
SMC restriction: prevention of hyperuricaemia in adult patients at intermediate risk of TLS in whom allopurinol is either unsuitable or contraindicated, such as:
• Those intolerant of allopurinol
• Those in whom allopurinol is contraindicated, e.g. patients with renal impairment
In a phase III, randomised, double-blind study in adults with haematologic malignancies at intermediate to high risk of TLS, febuxostat was significantly superior to a xanthine oxidase inhibitor at reducing serum uric acid levels.
Download detailed advice170KB (PDF)
Medicine details
- Medicine name:
- febuxostat (Adenuric)
- SMC ID:
- 1153/16
- Indication:
- for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumour Lysis Syndrome (TLS).
- Pharmaceutical company
- Menarini Pharmaceuticals UK
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 June 2016